



## Speaker

### Shih-Hsien Chuang, Ph.D.

莊士賢 博士

Director, Medicinal Chemistry Department,  
Institute of Pharmaceutics,  
Development Center for Biotechnology

## Site-Specific Trimannosyl Conjugation and ADC Capability in DCB

### Education :

Ph.D. in Chemistry, National Tsing-Hua University, Hsinchu, Taiwan  
Visiting scholar, Department of Biology, Johns Hopkins University  
BS in Chemistry, National Tsing-Hua University, Hsinchu, Taiwan

Dr. Chuang received his PhD degree in Medicinal Chemistry from National Tsing Hua University in 2005. He joined DCB and started his career in drug discovery since 2006. As a principal investigator in institute of pharmaceutics, Dr. Chuang led several drug discovery projects especially on oncology field. For example, the Nek2/Hec1 inhibitor against advanced refractory solid tumors collaborated with Taivex Therapeutics was in Phase I clinical trial. Besides, Dr. Chuang also focused on developing novel technology platforms such as next generation antibody-drug conjugates (ADC) and proteolysis targeting chimera (PROTAC). Dr. Chuang had over 20 papers published in peer-reviewed journals.